Korro Bio Inc (KRRO) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form S-3 - Registration statement under Securities Act of 1933

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]